[Federal Register Volume 60, Number 228 (Tuesday, November 28, 1995)]
[Notices]
[Page 58628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-28916]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made final findings of scientific misconduct in the following
case:
Tetsuya Matsuguchi, M.D., Ph.D., Dana-Farber Cancer Institute: On
November 3, 1995, ORI found that Tetsuya Matsuguchi, M.D., Ph.D.,
formerly a Harvard Medical School Research Fellow at the Dana-Farber
Cancer Institute, committed scientific misconduct by intentionally
falsifying data by artificially darkening one band each on two
autoradiographs in figures that he had prepared for a presentation at
an intramural research seminar and by altering three bands on the print
of an immunoblot included in Figure 2A of a paper published in the EMBO
Journal. This research was supported by a Public Health Service grant.
Dr. Matsuguchi has entered into a Voluntary Exclusion Agreement
with ORI in which he has accepted ORI's finding and has agreed to
exclude himself voluntarily, for the three (3) year period beginning
November 3, 1995:
(1) From any contracting or subcontracting with any agency of the
United States Government and from eligibility for, or involvement in,
Federal nonprocurement transactions (e.g., grants and cooperative
agreements), of the United States Government, as defined in 45 C.F.R.
Part 76 and 48 C.F.R. Subparts 9.4 and 309.4 (Debarment Regulations);
and
(2) From serving in any advisory capacity to PHS, including but not
limited to service on any PHS advisory committee, board, and/or peer
review committee, or as a consultant.
The above voluntary exclusion, however, shall not apply to Dr.
Matsuguchi's future training or practice of clinical medicine whether
as a medical student, resident, fellow, or licensed practitioner unless
that practice involves research or research training.
Dr. Matsuguchi has agreed to submit a letter to the EMBO Journal
requesting correction of the article entitled ``Tyrosine
phosphorylation of p85Vav in myeloid cells is regulated by GM-CSF,
IL-3, and Steel factor and is constitutively increased by p210BCR/
ABL'' (EMBO Journal 14:257-265, 1995) by retracting Figure 2A, because
Dr. Matsuguchi enhanced the Vav bands in lanes 2, 3, and 4 without the
knowledge of the other authors, and by substituting the correct Figure
2A.
FOR FURTHER INFORMATION CONTACT: Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-28916 Filed 11-27-95; 8:45 am]
BILLING CODE 4160-17-P
